Health Technology

Kyowa Kirin Co., Ltd.

In the news

SoftBank failures show it is time to break up Japan's conglomerates Feb 13, 2020
China stocks lead Friday's Asian sell-off after US plunge Feb 9, 2018
Kirin brewing up record profit in 2017 Feb 7, 2018
Drugmaker Kyowa Hakko Kirin sees profit doubling by 2020 Dec 14, 2017
Kirin hopes health ventures will heal its anemic growth Oct 25, 2017

See more articles on Kyowa Kirin Co., Ltd.

Business Summary

Kyowa Kirin Co., Ltd. engages in the manufacture and sale of medical and pharmaceutical products. It handles the research, development, production, and sale of in vitro diagnostic reagents and ethical drugs concerning renal anemia, leukemia, cancer, allergies, and hypertension. It also produces and sells medical and industrial raw materials such as amino acids, nucleic acid-related compounds, and healthcare products. The company was founded by Benzaburo Kato on July 1, 1949 and is headquartered in Tokyo, Japan.

Financial Highlights

Dec 2021	JPY	USD
Revenue	352,246M	3,205.93M
Gross Profit	253,894M	2,310.79M
Operating income	61,110M	556.18M
Income before tax	55,475M	504.90M
Net income	52,347M	476.43M
EBITDA	80,608M	733.64M
Diluted EPS	97.38	0.88
Dividends Per Share	46	0.41
Total Assets	921,872M	8,005.48M
Total liabilities	184,710M	1,604.01M
Total equity	737,162M	6,401.47M
Operating cash flow	86,548M	787.70M
	Currency in JPY	Currency in USD

Historical Data

JPY | USD

	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021
Revenue	353,380M	271,510M	305,820M	318,352M	352,246M
Gross Profit	215,972M	188,834M	215,129M	227,827M	253,894M
Operating income	62,209M	50,403M	53,354M	55,419M	61,110M
Income before tax	55,849M	66,841M	44,492M	52,263M	55,475M
Net income	42,899M	49,230M	37,674M	47,027M	52,347M
EBITDA	84,241M	66,646M	72,151M	75,885M	80,608M
Diluted EPS	78.30	99.29	43.12	87.49	97.38
Dividends Per Share	27	35	42	44	46
Total Assets	708,295M	741,982M	784,453M	801,290M	921,872M
Total liabilities	92,268M	92,589M	106,203M	102,893M	184,710M
Total equity	616,028M	649,621M	678,250M	698,396M	737,162M
Operating cash flow	64,902M	56,181M	53,655M	39,502M	86,548M

	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021
Revenue	3,151.41M	2,458.37M	2,805.40M	2,981.70M	3,205.93M
Gross Profit	1,926.02M	1,709.78M	1,973.46M	2,133.84M	2,310.79M
Operating income	554.77M	456.37M	489.43M	519.05M	556.18M
Income before tax	498.05M	605.20M	408.14M	489.49M	504.90M
Net income	382.57M	445.75M	345.59M	440.45M	476.43M
EBITDA	751.25M	603.44M	661.87M	710.74M	733.64M
Diluted EPS	0.69	0.89	0.39	0.81	0.88
Dividends Per Share	0.24	0.31	0.38	0.41	0.41
Total Assets	6,287.57M	6,762.81M	7,218.33M	7,761.05M	8,005.48M
Total liabilities	819.06M	843.90M	977.25M	996.59M	1,604.01M
Total equity	5,468.51M	5,920.98M	6,241.08M	6,764.45M	6,401.47M
Operating cash flow	578.79M	508.68M	492.19M	369.97M	787.70M

Valuation Measures

Dec 2021
PER	32.17
ROA	6.07%
ROE	7.29%
Operating margin	17.34%
Profit margin	14.86%

Key executives

President, CEO & Representative Director: Masashi Miyamoto
Executive Officer, Manager-Accounting & Finance: Motohiko Kawaguchi
Executive Officer, GM-Research & Development: Mitsuo Satoh
Representative Director & Executive Vice President: Yutaka Osawa
Executive Officer & General Manager-Sales: Hiroshi Sugitani

Shareholders

Kirin Holdings Co., Ltd. (53.4%)
Nomura Asset Management Co., Ltd. (3.5%)
Daiwa Asset Management Co. Ltd. (1.6%)
Nikko Asset Management Co., Ltd. (1.6%)
Massachusetts Financial Services Co. (1.4%)
The Vanguard Group, Inc. (1.1%)
BlackRock Fund Advisors (0.9%)
Mitsubishi UFJ Kokusai Asset Management Co., Ltd. (0.8%)
Norges Bank Investment Management (0.6%)
JPMorgan Asset Management (UK) Ltd. (0.5%)

Contact Details

Website:http://www.kyowa-kirin.co.jp
Address: Otemachi Financial City Grand Cube, 1-9-2 Otemachi, Tokyo, 100-0004, Japan
Phone: +81.3.5205.7200

Related Companies

Kyowa Kirin Australia Pty Ltd.
Kyowa Kirin Pharma FZ LLC
Kyowa Kirin Malaysia Sdn. Bhd.
Kyowa Kirin Korea Co., Ltd.
Kyowa Kirin Pharma SRL
Kyowa Kirin Pharma sro
Kyowa Kirin Austria GmbH
Kyowa Kirin SARL
Kyowa Kirin AB
Kyowa Kirin Pharma BV
Kyowa Kirin Holdings BV
Kyowa Kirin Farmaceutica SL
Kyowa Kirin Ireland Ltd.
Kyowa Kirin Canada, Inc.
Kyowa Kirin Frontier Co., Ltd.
Kyowa Medical Promotion Co., Ltd.
Kyowa Kirin GmbH
Strakan International SARL
Kyowa Kirin Plus Co., Ltd.
Kyowa Hakko Bio Co. Ltd. (Beijing)
Kyowa Hakko Bio (Shanghai) Trading Co., Ltd.
Kyowa Hakko Bio (Shanghai) Trading Co. Ltd. /Beijing Branch/
Kyowa Hakko Bio Shanghai Trading Co. Ltd. /Guangzhou/
Kyowa Hakko Kirin (Hong Kong) Co. Ltd.
Kyowa Hakko Kirin (Taiwan) Co. Ltd.
Kyowa Hakko Kirin (Singapore) Pte Ltd.
Kyowa Hakko Kirin China Pharmaceutical Co., Ltd.
Kyowa Hakko Kirin (Thailand) Co. Ltd.
ProStrakan SRL
Kyowa Hakko Kirin America, Inc.

Competitors

Genexine, Inc.
Innate Pharma SA Class A
FibroGen, Inc.
Tonix Pharmaceuticals Holding Corp.
Springworks Therapeutics, Inc.
Tetralogic Pharmaceuticals Corporation
Citius Pharmaceuticals Inc
Ikena Oncology, Inc.
Seagen, Inc.
Heron Therapeutics Inc
Prometheus Biosciences, Inc

Last Updated on 18 May, 2022